Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
24th February 2021 | Michael J Brown | 2,249 | Payment by withholding | $156.27 | $351,451.23 |
24th February 2021 | Michael J Brown | 7,236 | Grant/award etc. | $0.00 | |
1st January 2021 | Chandler Robinson | 2,327 | Payment by withholding | $6.12 | $14,241.24 |
1st January 2021 | Chandler Robinson | 6,724 | Exercise of derivative | $0.00 | |
1st January 2021 | Kim R Tsuchimoto | 1,231 | Exercise of derivative | $0.00 | |
1st January 2021 | Andrew Paul Mazar | 1,937 | Exercise of derivative | $0.00 | |
1st January 2021 | Kim R Tsuchimoto | 504 | Payment by withholding | $6.12 | $3,084.48 |
1st January 2021 | Andrew Paul Mazar | 671 | Payment by withholding | $6.12 | $4,106.52 |
31st December 2020 | Michael J Brown | 322 | Exercise of derivative | $0.00 | |
31st December 2020 | Arthur J Klausner | 322 | Exercise of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 6/10.
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014.
2nd March 2021
24th February 2021